Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eyepoint Pharmaceuticals Inc (NQ: EYPT )

6.040 +0.060 (+1.00%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 5, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 329,412
Open 5.970
Bid (Size) 5.780 (8)
Ask (Size) 6.190 (6)
Prev. Close 5.980
Today's Range 5.810 - 6.113
52wk Range 2.190 - 11.44
Shares Outstanding 34,301,926
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Is Alimera Sciences (ALIM) Stock Up 21% Today?
Alimera Sciences (ALIM) stock is taking off on Thursday after signing a major deal with EyePoint Pharmaceuticals (EYPT). 
Via InvestorPlace
EyePoint Pharma Offloads Its Commercially-Available Eye Implant For $82.5M Plus Royalties
EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) has agreed to sell Yutiq (fluocinolone acetonide intravitreal implant) 0.18mg to Alimera Sciences Inc (NASDAQ: ALIM).  
Via Benzinga

Performance

YTD
+65.48%
+65.48%
1 Month
-6.65%
-6.65%
3 Month
+86.42%
+86.42%
6 Month
+81.38%
+81.38%
1 Year
-29.77%
-29.77%

More News

Read More
Why EyePoint Pharmaceuticals Shares Are Shooting Higher Today
Via Benzinga
EyePoint Pharmaceuticals: Q1 Earnings Insights
Via Benzinga
R&D Activities for Treating Dry Eye Syndrome Resulting in Promising Pipeline of Treatments
Via FinancialNewsMedia
Exposures COVID-19
Earnings Preview: EyePoint Pharmaceuticals
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why IDEAYA Biosciences Shares Are Trading Higher By Around 27%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Super Micro Computer, Garrett Motion, Rackspace Technology And Other Big Stocks Moving Lower On Monday
Via Benzinga
Nasdaq Edges Higher; Procter & Gamble Posts Upbeat Earnings
Via Benzinga
EyePoint Pharmaceuticals Inc. (NASDAQ: EYPT) Near the Top of Equities by Percentage Gain on 4/21
Via Investor Brand Network
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Gold Down Over 1%; US Composite PMI Rises In April
Via Benzinga
US Stocks Mostly Lower; Nasdaq Down 50 Points
Via Benzinga
Why SAP Shares Are Trading Higher By Around 6%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Eyepoint Pharmaceuticals Inc. (NASDAQ: EYPT) Leading the Way in Monday Trading Based on Percentage Gain
Via Investor Brand Network
Finance Executives Look For Ways To Diversify Cash Strategies After Silicon Valley Bank's Fallout
Via Benzinga
EyePoint Pharma Posts Deeper Losses For Q4, Expects Cash Runway Into 2024
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
EYEPOINT ALERT: Bragar Eagel & Squire, P.C. is Investigating EyePoint Pharmaceuticals, Inc. on Behalf of EyePoint Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
EYEPOINT ALERT: Bragar Eagel & Squire, P.C. is Investigating EyePoint Pharmaceuticals, Inc. on Behalf of EyePoint Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
EYEPOINT ALERT: Bragar Eagel & Squire, P.C. is Investigating EyePoint Pharmaceuticals, Inc. on Behalf of EyePoint Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating GrafTech, BRP, Cantaloupe, and EyePoint and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating GrafTech, BRP, Cantaloupe, and EyePoint and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.